iMedi.co.uk

Aminoplasmal 10% Solution For Infusion

Informations for option: Aminoplasmal 10% Solution For Infusion, show other option

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT

Aminoplasmal 10% solution for infusion

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

The solution for infusion contains

Amino acids:

per 1 ml

per 250 ml

per 500 ml

per 1000 ml

Isoleucine

5.00 mg

1.25 g

2.50 g

5.00 g

Leucine

8.90 mg

2.23 g

4.45 g

8.90 g

Lysine acetate

5.74 mg

1.44 g

2.87 g

5.74 g

(equivalent to lysine)

(4.07 mg)

(102 g)

(2.04 g)

(4.07 g)

Lysine monohydrate

3.12 mg

0.78 g

1.56 g

3.12 g

(equivalent to lysine)

(2.78 mg)

(0.70 g)

(139 g)

(2.78 g)

Methionine

4.40 mg

1.10 g

2.20 g

4.40 g

Phenylalanine

4.70 mg

1.18 g

2.35 g

4.70 g

Threonine

4.20 mg

1.05 g

2.10 g

4.20 g

Tryptophan

1.60 mg

0.40 g

0.80 g

1.60 g

Valine

6.20 mg

1.55 g

3.10 g

6.20 g

Arginine

11.50 mg

2.88 g

5.75 g

11.50 g

Histidine

3.00 mg

0.75 g

1.50 g

3.00 g

Alanine

10.50 mg

2.63 g

5.25 g

10.50 g

Glycine

12.00 mg

3.00 g

6.00 g

12.00 g

Aspartic acid

5.60 mg

1.40 g

2.80 g

5.60 g

Glutamic acid

7.20 mg

1.80 g

3.60 g

7.20 g

Proline

5.50 mg

1.38 g

2.75 g

5.50 g

Serine

2.30 mg

0.58 g

1.15 g

2.30 g

Tyrosine

0.40 mg

0.10 g

0.20 g

0.40 g

Total amino acids    100    g/l

Total nitrogen    15.8 g/l

Caloric value:    1675    kJ/l    =    400 kcal/l

Theoretical osmolarity:    864    mOsm/l

Titration acidity (to pH 7.4): approx. 20 mmol/l pH:    5.7    - 6.3

Electrolyte concentrations: mmol/l Acetate    28

Citrate    2.0

For the full list of excipients, see section 6.1.

3    PHARMACEUTICAL FORM

Solution for infusion

Clear, colourless up to faintly straw-coloured solution

4    CLINICAL PARTICULARS

4.1    Therapeutic indications

Supply of amino acids for parenteral nutrition, when oral or enteral nutrition is impossible, insufficient or contra-indicated. For adults, adolescents and children over 2 years of age.

In parenteral nutrition, amino acid infusions should always be combined with adequate calorie supply, e.g. in the form of carbohydrate infusions.

4.2    Posology and method of administration

Posology

The dosage is adjusted according to the individual need of amino acids and fluid depending on the clinical condition of the patient (nutritional status and/or degree of nitrogen catabolism due to underlying disease).

Adults and adolescents from 14 to 17 years:

Average daily dose:

10 - 20 ml /kg body weight (BW)= 1.0-2.0 g amino acids/kg BW

= 700-1400 ml for a 70 kg patient

Maximum daily dose:

20 ml/kg BW    = 2.0 g amino acids/kg BW

= 140 g amino acids for a 70 kg patient = 1400 ml for a 70 kg patient

Maximum infusion and drop rates, respectively:

1 ml/kg BW/h    = 0.1 g amino acids/kg BW/h

= 25 drops/min for a 70 kg patient = 1.17 ml/min for a 70 kg patient

Children and adolescents 2 to 13 years:

The dosages for this age group as stated below are average values for guidance. The exact dosage should be adjusted individually according to age, developmental stage and prevailing disease.

Daily dose for children from 2 to 4 years:

15 ml/kg BW    = 1.5 g amino acids/kg BW

Daily dose for children from 5 to 13 years:

10 ml/kg BW    = 1.0 g amino acids/kg BW

Maximum infusion rate:

1 ml/kg BW/h    = 0.1 g amino acids/kg BW/h

Duration of use

It can be administered as long as there is an indication for parenteral nutrition. Method of administration

Intravenous use (central venous infusion).

Aminoplasmal 10% is only one component of parenteral nutrition. In parenteral nutrition, amino acid supply must be combined with supply of calorie sources, essential fatty acids, electrolytes, vitamins, and trace elements.

4.3    Contraindications

•    Hypersensitivity to the active substances or to any of the excipients listed in section 6.1

•    Congenital abnormalities of amino acid metabolism

•    Severe circulation disorders with vital risk (e.g. shock)

•    Hypoxia

•    Metabolic acidosis

•    Advanced liver disease

•    Severe renal insufficiency without access to haemofiltration or haemodialysis

•    Children under 2 years of age because the nutrient ratios do not properly meet the special paediatric requirements

•    General contraindications of infusion therapy:

-    uncompensated cardiac insufficiency

-    acute pulmonary oedema

-    hyperhydration

4.4    Special warnings and precautions for use

Aminoplasmal 10% should only be administered after careful benefit-risk assessment in the presence of disorders of amino acid metabolism of other origin than stated under section 4.3.

Hypotonic dehydration should be corrected by adequate supply of fluid and electrolytes prior to parenteral nutrition.

In cases of hypokalaemia and/or hyponatraemia adequate amounts of potassium and/or sodium should be supplied.

In patients with liver or renal insufficiency, the dose must be adjusted according to individual requirements.

Caution should be exercised in patients with increased serum osmolarity.

Serum electrolytes, blood glucose, fluid balance, acid-base balance and renal function (BUN, creatinine) should be monitored regularly.

Monitoring should also include serum protein and liver function tests.

Care should be exercised in the administration of large volume infusion fluids to patients with cardiac insufficiency.

Aminoplasmal 10% is applicable as part of a total parenteral nutrition regimen in combination with adequate amounts of energy supplements (carbohydrate solutions, fat emulsions), vitamins, trace elements and electrolytes.

The site of infusion should be checked daily for signs of inflammation or infection.

4.5    Interaction with other medicinal products and other forms of interaction

None known

4.6    Fertility, pregnancy and lactation

Studies in pregnant or breast-feeding women have not been conducted with this medicinal product. There are no pre-clinical data regarding the administration of Aminoplasmal 10% during pregnancy. Aminoplasmal 10% should therefore be administered with caution during pregnancy and lactation and only if deemed clearly indicated after assessment of its benefits and possible risks.

4.7    Effects on ability to drive and use machines

Not applicable

4.8    Undesirable effects

Undesirable effects that, however, are not specifically related to the product but to parenteral nutrition in general may occur, especially at the beginning of parenteral nutrition.

Listing of undesirable effects

Undesirable effects are listed according to their frequencies as follows:

Very common (> 1/10)

Common    (> 1/100 to < 1/10)

(> 1/1,000 to < 1/100)

Uncommon Rare Very rare Not known


(> 1/10,000 to < 1/1,000)

(< 1/10,000)

(frequency cannot be estimated from the available data)

Immune system disorders Not known: Allergic reactions

Gastrointestinal disorders

Uncommon: Nausea, vomiting

General disorders and administration site conditions

Uncommon: Headache, shivering, fever

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse via the MHRA Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9 Overdose

Symptoms

Overdose or too high infusion rates may lead to intolerance reactions manifesting in the form of shivering, nausea, vomiting, and renal amino acid losses.

Treatment

If intolerance reactions occur, the amino acid infusion should be interrupted temporarily and resumed later on at a lower infusion rate

5    PHARMACOLOGICAL PROPERTIES

5.1    Pharmacodynamic properties

Pharmacotherapeutic group: Blood substitutes and perfusion solutions, i.v. solutions, solutions for parenteral nutrition, ATC code: B05BA01.

The aim of parenteral nutrition is the supply of all nutrients necessary for the growth, maintenance and regeneration of body tissues etc.

Amino acids are of special importance as they partly are essential for protein synthesis. Intravenously administered amino acids are incorporated in the respective intravascular and intracellular amino acid pools. Both endogenous and exogenous amino acids serve as substrate for the synthesis of functional and structural proteins.

To prevent the metabolisation of amino acids for energy production, and also to fuel the other energy consuming processes in the organism, simultaneous energy supply (in the form of carbohydrate or fat) is necessary.

5.2    Pharmacokinetic properties

Because Aminoplasmal 10% is infused intravenously, the bio-availability of the amino acids contained in the solution is 100 %.

The composition of Aminoplasmal 10% is based upon the results of clinical investigations of the metabolism of intravenously administered amino acids. The quantities of the amino acids contained in Aminoplasmal 10% have been chosen so that a homogenous increase of the concentrations of all plasma amino acids is achieved. The physiological relations of plasma amino acids, i. e. the amino acid homeostasis is thus maintained during infusion of Aminoplasmal 10%.

Amino acids, that do not enter protein synthesis, are metabolized as follows. The amino group is separated from the carbon skeleton by transamination. The carbon chain is either oxidized directly to CO2 or utilized as substrate for gluconeogenesis in the liver. The amino group is also metabolized in the liver to urea.

5.3    Preclinical safety data

Preclinical studies have not been performed with this medicinal product.

Aminoplasmal 10% only contains amino acids that are substrates of human metabolism.

Therefore, no toxic reactions are expected to occur as long as the indications, contraindications and dosage recommendations are duly observed.

6    PHARMACEUTICAL PARTICULARS

6.1    List of excipients

Acetylcysteine

Citric acid monohydrate (for pH-adjustment)

Water for injections

6.2    Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3    Shelf life

Shelf life in the unopened container 3 years

Shelf life after first opening the container

The medicinal product should be used immediately.

Shelf life after mixing with other components

From the microbiological point of view, mixtures should be administered immediately after preparation. If not administered immediately, storage times and conditions of mixtures prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 °C - 8 °C, unless mixing has taken place under controlled and validated aseptic conditions.

6.4    Special precautions for storage

Keep the container in the outer carton in order to protect from light.

Do not freeze.

Cool storage of the solution, below 15 °C, may lead to formation of crystals, that can, however, be easily dissolved by gentle warming at 25 °C until dissolution is complete. Shake container gently to ensure homogeneity.

6.5    Nature and contents of container

Bottles of colourless glass (type II), sealed with chlorobutyl-rubber stoppers.

Contents:    250 ml, available in packs of 10 bottles

500 ml, available in packs of 10 bottles 1000 ml, available in packs of 6 bottles

Not all pack sizes may be marketed.

6.6    Special precautions for disposal

No special requirements for disposal.

Containers are for single use only. Discard any unused contents remaining after the end of the infusion.

The solution should only be used if the closure of the container is not damaged and if the solution is clear.

Use a sterile giving set for administration.

If in the setting of complete parenteral nutrition it is necessary to add other nutrients such as carbohydrates, lipids, vitamins and trace elements to this medicinal product, admixing must be performed under strict aseptic conditions. Mix well after admixture of any additive. Pay special attention to compatibility.

7    MARKETING AUTHORISATION HOLDER

B. Braun Melsungen AG Carl-Braun-StraBe 1 34212 Melsungen Germany

Postal address B. Braun Melsungen AG 34209 Melsungen Germany

Phone:    +49-5661-71-0

Fax:    +49-5661-4567

8    MARKETING AUTHORISATION NUMBER(S)

PL 03551/0104

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

22/10/2009

10 DATE OF REVISION OF THE TEXT 09/2014